The 23 most recent market catalysts affecting $TEVA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Neutral
Impact 55
Oppenheimer Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $50
Oppenheimer's initiation of coverage on Teva Pharmaceutical Industries with an 'Outperform' rating and a $50 price target is a positive development for the company. Analyst initiat…
Sep 18, 2026
Corporate Catalyst
Bullish
Impact 65
Teva Pharmaceuticals Presents Data Showing UZEDY Improves Treatment Continuity, Reduces Hospitalizations And Cuts Healthcare Costs In Schizophrenia And Bipolar I Disorder
Teva Pharmaceuticals released new real-world data for its extended-release injectable UZEDY, demonstrating favorable treatment continuity, reduced emergency room visits and hospita…
Sep 18, 2026
Corporate Catalyst
Bullish
Impact 65
Teva Presents New SOLARIS Data Showing TEV-'749 Maintained Schizophrenia Stabilization And Supported Remission In Long-Term Use
Teva Pharmaceuticals presented new post hoc data from its Phase 3 SOLARIS trial for TEV-'749, an investigational long-acting injectable for schizophrenia. The data indicates that t…
Sep 15, 2026
Corporate Catalyst
Neutral
Impact 75
Teva's Shares Now Trade Directly on the NYSE — Here's What Else Changed
Teva's recent activities signal a strategic pivot aimed at improving its financial health and market accessibility. The $4.9 billion debt refinancing, replacing higher-interest not…
Sep 14, 2026
Corporate Catalyst
Neutral
Impact 65
Teva Pharmaceutical Announces Ordinary Shares Begin Trading Directly On NYSE Monday, September 14 Under Ticker TEVA
This announcement signifies a corporate restructuring of Teva's listing strategy, moving from potentially multiple listings or an ADR program to a direct NYSE listing. This typical…
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 65
Teva Priced Approximately $4.9B (Equivalent) of Senior Notes
Teva has priced a significant offering of senior notes totaling approximately $4.9 billion. This move is a strategic refinancing effort, as the company intends to use the proceeds …
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 65
Leerink Partners Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $45
Leerink Partners' initiation of coverage on Teva Pharmaceutical Industries with an 'Outperform' rating and a $45 price target signals a positive outlook from a new institutional an…
Sep 7, 2026
Corporate Catalyst
Neutral
Impact 65
Teva Pharmaceutical Industries Announced Its Intention To Issue Senior Notes Through Its Special Purpose Finance Subsidiaries
Teva's intention to issue senior notes is a corporate finance event. The immediate impact on TEVA stock is likely neutral to slightly positive, as it suggests proactive balance she…
Sep 4, 2026
Corporate Catalyst
Bullish
Impact 55
UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $48
UBS analyst Ashwani Verma maintained a 'Buy' rating on Teva Pharmaceutical Industries and raised the price target from $42 to $48. This action signals increased confidence from a m…
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 75
Teva Reports Significant Prevention Of Gluten-Induced Damage in New Study
Teva Pharmaceutical Industries reported encouraging Phase 2a clinical trial results for TEV-408, an anti-interleukin-15 monoclonal antibody for celiac disease. The drug met its pri…
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 75
Teva Stock Rises After TEV '408 Meets Primary Endpoint in Celiac Disease Study
Teva Pharmaceutical Industries Ltd. announced that its investigational drug, TEV '408, met its primary endpoint in a Phase 2a study for celiac disease, demonstrating statistically …
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 85
Teva Pharmaceutical Industries shares are trading higher after the company announced topline results from an ongoing Phase 2a study of TEV ‘408. The study met its primary endpoint.
This headline represents a significant corporate catalyst for Teva Pharmaceutical Industries. Positive topline results from a Phase 2a study, especially meeting its primary endpoin…
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 75
Teva Says Topline Results From Ongoing Phase 2a Study Of TEV ‘408 For Celiac Disease Met Its Primary Endpoint, Demonstrating Statistically Significant And Clinically Meaningful Prevention Of Gluten-induced Intestinal Damage Versus Placebo At Week 8
Teva Pharmaceutical Industries Ltd. announced positive topline results from its Phase 2a study of TEV '408, an investigational drug for celiac disease. The study met its primary en…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 65
Teva And Trump Administration Commit To Lowering Select Medicaid Drug Costs
Teva Pharmaceuticals has committed to working with the Trump Administration to reduce the cost of certain Medicaid drugs. This initiative, if finalized, would align U.S. Medicaid p…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 75
Teva Pharmaceuticals' New Drug Application For Ecopipam Gets FDA Acceptance To Treat Pediatric Patients With Tourette Syndrome
Teva Pharmaceuticals announced that the FDA has accepted its New Drug Application (NDA) for ecopipam, a novel treatment for pediatric Tourette syndrome, setting a PDUFA date for la…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $42
Barclays analyst Glen Santangelo maintained an 'Overweight' rating on Teva Pharmaceutical Industries and raised the price target from $40 to $42. This action signals a continued bu…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 85
Teva's Innovative Drug Portfolio Fuels Growth as Company Raises Outlook, Transitions to Direct NYSE Listing
Teva's 8-K filing reveals a mixed Q2 earnings report with adjusted earnings missing consensus but sales beating expectations, primarily due to robust growth in its innovative drug …
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 85
Teva Pharmaceutical shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY26 sales guidance with its midpoint above estimates.
This headline represents a significant corporate catalyst for Teva Pharmaceutical. The better-than-expected Q2 sales indicate strong operational performance and potentially success…
Jul 29, 2026
Corporate Catalyst
Bearish
Impact 75
Teva Pharmaceutical Indus Lowers FY2026 Adj EPS Guidance from $2.57-$2.77 to $1.91-$2.11 vs $2.04 Est; Raises FY2026 Sales Guidance from $16.400B-$16.800B to $16.500B-$16.850B vs $16.618B Est
Teva Pharmaceutical Industries (TEVA) has updated its FY2026 financial guidance, notably reducing its adjusted EPS range from $2.57-$2.77 to $1.91-$2.11, which is below the analyst…
Jul 29, 2026
Corporate Catalyst
Neutral
Impact 65
Teva Announces Replacement Of ADS Program With Direct NYSE Listing Of Ordinary Shares On One-For-One Basis; Trading Begins September 14, 2026
This announcement is a structural corporate catalyst for Teva. The replacement of an ADS program with a direct NYSE listing of ordinary shares on a one-for-one basis simplifies the…
Jul 29, 2026
Corporate Catalyst
Bearish
Impact 95
Teva Pharmaceutical Indus Q2 Adj. EPS $0.02 Misses $0.25 Estimate, Sales $4.142B Beat $4.047B Estimate
Teva Pharmaceutical Industries announced its Q2 earnings, revealing a substantial miss on adjusted earnings per share, falling short of analyst expectations by 92%. This significan…
Jul 22, 2026
Geopolitical Risk
Bearish
Impact 95
Shares of generic drug companies are trading lower after President Trump announced that imported generics will be subject to a 100% import tariff following a two-year grace period in order to encourage reshoring of pharma manufacturing.
The imposition of a 100% import tariff on generic drugs after a two-year grace period is a highly disruptive policy. It aims to incentivize the reshoring of pharmaceutical manufact…
Jul 13, 2026
Corporate Catalyst
Bearish
Impact 65
U.S. Appeals Court Revives Teva Pharmaceuticals' Lawsuit Against Eli Lilly Over Alleged Violation Of Settlement Agreement
The U.S. Appeals Court's decision to revive Teva Pharmaceuticals' lawsuit against Eli Lilly over an alleged violation of a settlement agreement is a significant development. This r…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.